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Abstract
Chromosomal instability (CIN) has been implicated in multidrug resistance and the silencing of the ceramide
transporter, CERT, promotes sensitization to diverse cytotoxics. An improved understanding of mechanisms
governing multidrug sensitization might provide insight into pathways contributing to the death of CIN cancer
cells. Using an integrative functional genomics approach, we find that CERT-specific multidrug sensitization is
associated with enhanced autophagosome–lysosome flux, resulting from the expression of LAMP2 following
CERT silencing in colorectal and HER2+ breast cancer cell lines. Live cell microscopy analysis revealed that CERT
depletion induces LAMP2-dependent death of polyploid cells following exit from mitosis in the presence of
paclitaxel. We find that CERT is relatively over-expressed in HER2+ breast cancer and CERT protein expression
acts as an independent prognostic variable and predictor of outcome in adjuvant chemotherapy-treated patients
with primary breast cancer. These data suggest that the induction of LAMP2-dependent autophagic flux through
CERT targeting may provide a rational approach to enhance multidrug sensitization and potentiate the death of
polyploid cells following paclitaxel exposure to limit the acquisition of CIN and intra-tumour heterogeneity.
Copyright  2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Drug resistance is associated with significant treat-
ment morbidity and impairment of quality of life. The
ceramide pathway has been implicated in the cellu-
lar response to cytotoxic chemotherapy, and enzymes
which impair ceramide accumulation in response to
drug exposure have been associated with multidrug
resistance [1]. We recently identified the ceramide
transporter CERT through a multidrug sensitivity
RNAi screen that enhanced sensitivity to paclitaxel,
cisplatin, 5-FU and doxorubicin when silenced from
multiple cancer cell lines [HCT116 (colon carci-
noma), MDA-MB-231 (breast adenocarcinoma) and
A549 (non-small cell lung carcinoma)] [2]. CERT
transports ceramide from the endoplasmic reticulum
(ER) to the Golgi apparatus where it is converted into
sphingomyelin [3]. We found that CERT was relatively
over-expressed in paclitaxel-resistant ovarian cancer
and was one of six genes included in a functional meta-
gene, predictive of combination-chemotherapy drug
sensitivity in breast cancer [4].
Through the same RNAi screen, we identified sev-
eral genes whose depletion induced both polyploidy
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and paclitaxel resistance, indicating that pathways
monitoring chromosomal stability and taxane sensitiv-
ity may be related. Consistent with this hypothesis, we
have confirmed that CIN is associated with paclitaxel
resistance in a small clinical trial cohort of patients with
ovarian cancer [5]. Follow-up analysis has revealed that
CIN appears to be associated with multidrug resistance
that we hypothesize may result from tumour hetero-
geneity between cancer cells fostering diversity and
evolutionary robustness or an intrinsic aneuploidy tol-
erant state [6].
We reasoned that understanding the molecular path-
ways responsible for cell death following CERT deple-
tion and paclitaxel exposure may offer a broader
insight into mechanisms regulating mitotic catastro-
phe and suggest therapeutic opportunities to specifi-
cally limit the development of chromosomally unsta-
ble cells. Here, through parallel integrative genomics
approaches, we investigate the role of CERT in cancer
drug-induced cell death.
Materials and methods
siRNA transfections and paclitaxel treatment
All siRNAs were obtained from Dharmacon. Unless
otherwise stated, all siRNA transfections were per-
formed using reverse transfection methods with Lipo-
fectamine RNAiMax reagent (Invitrogen) at 25 nM
final concentration of siRNA, and after 48 h of siRNA
transfection the cells were treated with 25 nM pacli-
taxel or vehicle control.
CERT microarray expression profiling
HCT116 cells were transfected with either siCON
or siCERT and treated in triplicate with paclitaxel,
C6-ceramide or vehicle control for 8 h for use on
HuEx-1_0-st-v2 exon arrays (Affymetrix) (for detailed
analysis of exon array, see Supporting information,
Supplementary methods).
Taqman Gene Expression Assays (Applied Biosys-
tems) were used according to the manufacturer’s
instructions in order to validate gene expression using
qPCR.
Cell line drug response assays
Cells were plated into 96-well tissue culture micro-
plates at an initial seeding density of 4000 cells/well
for siRNA reverse transfection. After 48 h of pacli-
taxel or vehicle control treatment, cell viability was
assayed using the Celltiter-Blue Cell Viability Assay
(Promega), according to the manufacturer’s instruc-
tions.
LC3 immunoblotting
Cells were plated into six-well tissue culture micro-
plates at an initial seeding density of 300 000 cells/well
for siRNA reverse transfection. The cells were then
harvested at 24 h after paclitaxel or vehicle con-
trol treatment or at other specified time points.
Immunoblotting was performed with primary anti-LC3
antibodies (Nanotools), using standard immunoblotting
protocols. Where relevant, the protease inhibitor leu-
peptin (Sigma-Aldrich) was used at a final concentra-
tion of 1 µg/ml.
Immunofluorescence microscopy
Cells were fixed using PTEMF (20 mM PIPES, pH
6.8, 10 mM EGTA, 1 mM MgCl2, 0.2% Triton X100
and 4% formaldehyde) for 10 min at room temper-
ature. Primary antibodies were diluted as follows in
PBS + 3% BSA anti-LAMP2 (Abcam) 1/1000. Cross-
adsorbed secondary antibodies were used (Molecular
Probes). 3D image stacks were acquired in 0.2 µm
steps, using a ×100 oil NA 1.4 objective on an Olym-
pus Deltavision Personal microscope (API) equipped
with a DAPI–FITC–Rhod/TR-CY5 filter set (Chroma)
and a Coolsnap HQ camera. The 3D image stacks were
deconvolved with SoftWorx (API).
Live cell imaging
For live cell imaging H2B-mRFP HCT116 cells were
monitored at 37 ◦C and 5% CO2 in LabTech II
(LabTech) chambers. Cells were plated into cham-
ber slides for reverse transfection and treated with
paclitaxel or vehicle control. Images were acquired
every 10 min for 48 h using a ×40 oil NA 1.3 objec-
tive on an Olympus Deltavision Personal microscope
(API) equipped with a DAPI–FITC–Rhod/TR-CY5
(Chroma) filter set and environmental chamber.
Tissue microarray cohort
Archival paraffin-embedded breast cancer tissue was
obtained from 356 patients diagnosed at Leeds Teach-
ing Hospitals NHS Trust between 1983 and 1997.
Tissue microarrays (TMAs) were constructed contain-
ing cores, 0.6 mm in diameter and 4 µm in thick-
ness, selected from representative tumour areas as
determined by a consultant breast histopathologist
(AMH) from haematoxylin and eosin (H&E)-stained
sections. Full clinico-pathological data was available.
The majority of chemotherapy-treated patients were
given cyclophosphamide, methotrexate and fluorouracil
5-FU (CMF) or fluorouracil 5-FU, epirubicin and
cyclophosphamide (FEC) treatment. Ethical approval
was obtained (Leeds East 06/Q1206/180).
Following deparaffinization, an antigen retrieval step
was performed. Tissue sections were incubated with
CERT rabbit polyclonal antibody (Bethyl Labora-
tories), dilution 1 : 3500 for 1 h. Biotinylated sec-
ondary antibodies were used followed by strepta-
vidin–biotin–peroxidase complex. Peroxidase was
localized using diaminobenzidine, with counterstaining
with Mayer’s haematoxyin. A known positive control
was used with each batch of staining. Slides were
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viewed by two independent scorers blinded to each
other’s findings.
CERT localized to the cytoplasm. Scoring was
performed for both the percentage and intensity of
staining, using a scale of 0–3 (with 0 = tumours
with no staining whatsoever; 1 = tumours with rare
scattered positive staining; 2 = tumours with moderate
to strong staining but with some cells showing no
readily detected staining; and 3 = tumours with strong
staining, uniformly visualized over the whole section).
A score of percentage positive staining cells × the
intensity score was calculated and this was defined as
the quickscore [7].
A maximally selected rank statistic [8] was used
on all 356 patients to detect a CERT expression
quickscore threshold for separating good from poor
prognosis. The R-package maxstat [9] was used to
derive the reported threshold of 175. The reported
p value of 0.0030 (Figure 5A) is conservative and
adjusted for the selection of the threshold, and thus
avoids the problem of reporting over-optimistic low
p values arising from the selection process. Based on
this threshold (quickscore = 175), CERT expression
was grouped into high and low expression for the
whole dataset. Survival analysis was performed with
a univariate Cox-proportional hazard regression and
a log-rank statistic was used for significance testing
between the CERT-high and CERT-low groups.
Results
CERT depletion results in ceramide accumulation
CERT silencing was previously reported to sensi-
tize the HCT116 colorectal cancer, MDA-MB-231
breast and A549 non-small cell lung cancer cell
lines to multiple clinically relevant cytotoxics in a
kinome library RNAi screen [2]. CERT transports long-
chain ceramides (C14–20) and short-chain fluorescent
ceramide analogues from the endoplasmic reticulum to
the Golgi apparatus [3]. We hypothesized that CERT
silencing in the presence of paclitaxel might mimic
the effect of ceramide exposure through the attenuation
of ceramide transport from the endoplasmic reticulum
(ER) to the Golgi and its subsequent conversion into
sphingomyelin. We confirmed that depletion of CERT
by RNAi (siCERT) in HCT116 cells results in atten-
uation of ceramide transport with ceramide confined
to membranous and diffuse cytoplasmic structures, in
contrast to control transfected cells (siCON), in which
ceramide is localized to Golgi-like punctate perinuclear
regions (see Supporting information, Figure S1A) [10].
To establish whether CERT depletion might induce
alterations in ceramide levels that could be exacer-
bated by paclitaxel exposure, we analysed lipid extracts
for ceramide content by mass spectrometry. Paclitaxel
treatment (25 nM for 48 h) of siCON-transfected cells
did not significantly increase total ceramide levels (see
Supporting information, Figure S1B). CERT depletion
resulted in an increase in total ceramide levels relative
to siCON-transfected cells (p = 0.008) and the combi-
nation of siCERT with paclitaxel treatment resulted in
a synergistic increase in total cellular ceramide levels
(p = 0.0001) relative to CERT silencing or paclitaxel
treatment alone.
Transcriptomic analysis reveals a CERT-specific
response
We hypothesized that the CERT-specific paclitaxel
sensitization phenotype may be attributable to two
mechanisms; the first primes the cell for paclitaxel-
induced cell death following CERT silencing, the
second mechanism might be attributable to a response
derived from ceramide sequestration within the ER that
acts synergistically to enhance cell death. We reasoned
that through the identification of a CERT-specific
and ER-restricted ceramide transcriptional response,
mediators of this process might be identifiable.
First, we addressed whether CERT depletion is asso-
ciated with a specific transcriptional response that
might inform upon the mechanism through which
CERT silencing primes cells for paclitaxel-induced
death. We used microarray expression analysis of
HCT116 cells to identify genes differentially regu-
lated following CERT depletion in the presence of
ceramide, paclitaxel or DMSO vehicle control com-
pared to the same treatments in siCON-transfected
cells in three independent experiments. We identi-
fied a common CERT-specific transcriptional response
(Figure 1A) and 24 genes from this analysis were
selected for qPCR validation. The analysis was per-
formed on the same triplicate biological samples used
for the microarray analysis, and we found that microar-
ray profiles correlated closely with gene expression
changes validated by qPCR (R = 0.97), as previously
described [11], indicating the reliability of gene expres-
sion changes quantified by Affymetrix HuEx-1_0-st-v2
array profiling (Figure 1B).
CERT depletion induces LAMP2, which is required
for paclitaxel cell death
Genes expressed following CERT depletion might
prime cells for subsequent cell death initiated by
paclitaxel. Silencing the expression of these genes
through RNAi might antagonize paclitaxel response
and siCERT-specific paclitaxel sensitization. Seven
genes (CPA4,FYCO1,KLF6,LAMP2,MDK,WDFY1 and
WIPI1 ), whose expression was induced following
CERT depletion (and validated by qPCR), were
silenced by RNAi in HCT116 cells and paclitaxel sen-
sitivity was assessed. Two of the seven genes pro-
moted paclitaxel resistance when silenced in HCT116
cells: LAMP2, encoding a lysosomal membrane pro-
tein [12]; and CPA4, a carboxypeptidase with unknown
specific substrate (Figure 1C). CERT silencing induced
a 0.56 log2-fold change in levels of LAMP2 expres-
sion (Figure 1B), corresponding to a 47% increase in
the expression of LAMP2. The induction of LAMP2
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Figure 1. CERT gene expression signature and investigation of pathways mediating paclitaxel-induced cell death. (A) Heat map of
differentially expressed genes in HCT116 cells 8 h after paclitaxel, C6-ceramide or vehicle control treatment, 48 h following siCERT
transfection. Expression of this gene signature in siCON-transfected paclitaxel and C6-ceramide-treated cells provided for comparison.
(B) Graph of qPCR validation of 24 genes that are differentially expressed following CERT depletion. Error bars represent standard deviation
(SD) across triplicate experiments. (C) Graph of relative cell number following transfection of siCON, siCERT, siCPA4, siLAMP2 or siCERT and
siLAMP2 and vehicle control or paclitaxel treatment. Data were normalized to cell number in siCON/vehicle control or siCON/paclitaxel for
paclitaxel-treated experiments. Error bars represent SD across six replicates/condition. (D) Western blot analysis showing LAMP2 protein
expression 24 h after paclitaxel or vehicle control treatment following 48 h of siCON or siCERT transfection. (E) Graph of qPCR assessment
of gene expression of LAMP2 and LAMP2A specifically.
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protein following CERT silencing and efficient knock-
down of LAMP2 protein by RNAi was confirmed
(Figure 1D). qPCR quantification using primers spe-
cific to the LAMP2A isoform and to all LAMP2 splice
variants revealed an increase in expression of LAMP2,
with a greater specific increase in the LAMP2A iso-
form (Figure 1E). To assess whether siCERT-mediated
paclitaxel sensitization was dependent upon LAMP2
expression, both CERT and LAMP2 were co-depleted
and paclitaxel sensitivity was assessed. siLAMP2 abro-
gated the ability of siCERT to sensitize cells to pacli-
taxel exposure (Figure 1C). Co-silencing of both CERT
and LAMP2 was confirmed by qPCR (see Supporting
information, Figure S1C), and antagonizm of pacli-
taxel was confirmed for two separate siLAMP2 siRNA
oligonucleotide sequences (see Supporting information,
Figure S1D).
Ceramide treatment following CERT silencing
initiates a specific transcriptional response
CERT depletion attenuates the transport of exogenous
ceramide from the ER to the Golgi and promotes a
synergistic increase in cellular ceramide levels with
paclitaxel. We hypothesized that the rise in cellular
ceramide, restricted to the ER compartment following
CERT depletion, might contribute to cellular cytotox-
icity coordinated with a CERT-specific transcriptional
response.
To investigate the transcriptional response attri-
butable to ceramide that is likely to be restricted to
the ER following CERT silencing, we asked what gene
sets were significantly altered in HCT116 cells treated
with ceramide on a CERT-depleted background, rela-
tive to ceramide-treated siCON-transfected cells. The
autophagy process network (Metacore, GeneGo Inc.)
was significantly altered following ceramide treatment
of CERT-depleted cells compared to ceramide treat-
ment of HCT116 cells with proficient CERT transport
(Figure 2A; p = 3.5E-05).
CERT depletion and paclitaxel exposure initiates an
autophagy response
Given the observations that: (a) CERT depletion
induces a synergistic rise in cellular ceramide in
the presence of paclitaxel; (b) ceramide treatment of
CERT-depleted cells results in an autophagic tran-
scriptional response; and (c) LAMP2, induced follow-
ing CERT depletion, can antagonize paclitaxel cell
death when silenced from cells, we addressed whether
autophagy induction might occur following pacli-
taxel treatment of CERT-depleted cells. Lipidation of
endogenous microtubule-associated protein light chain
3 (LC3) was studied in HCT116 cells following CERT
silencing and paclitaxel exposure. Following transfec-
tion of siCON and paclitaxel treatment, there was min-
imal change in LC3-I (unlipidated LC3) or LC3-II (lip-
idated LC3) levels compared to vehicle control-treated
HCT116 cells (Figure 2B). Similarly, CERT silencing
in the absence of drug treatment did not significantly
alter LC3-I or LC3-II levels. The combination of CERT
silencing and paclitaxel treatment resulted in a reduc-
tion of both LC3-I and LC3-II, suggestive of autophagy
flux induction. Consistent with the degradation of LC3
by lysosomal proteases, addition of the lysosomal pro-
tease inhibitor, leupeptin, resulted in the reappearance
of LC3-I and LC3-II in siCERT cells treated with pacli-
taxel (see Supporting information, Figure S1E).
CERT-mediated paclitaxel sensitization is
LAMP2-dependent
It has been proposed that the tethering of the
autophagosome to the lysosomal membrane is a rate-
limiting step that defines the life-span of autophago-
somes [13]. The expression of LAMP2, encoding a
lysosomal membrane protein [12], is induced follow-
ing CERT depletion and LAMP2 silencing antago-
nizes paclitaxel sensitization on a CERT depleted back-
ground. Given the role of lysosomal proteases in tax-
ane sensitivity [14,15], we speculated that LAMP2
may contribute to paclitaxel sensitization through
autophagic cell death. Supporting the role of LAMP2
in siCERT/paclitaxel-induced autophagy response and
LC3 degradation, LAMP2 silencing attenuated LC3
degradation following CERT and LAMP2 co-depletion
(Figure 2B).
Cells were assayed at 12, 24, 48 and 72 h for apop-
totic activity, as measured by caspase 3/7 activity, and
for LC3-I and LC3-II expression (Figure 2C). Maxi-
mal reduction of LC3-I and LC3-II following siCERT
and paclitaxel was observed at 12 h with reappearance
of both moieties by 48 h. In contrast, maximal apop-
totic activity of siCERT- and siCON-transfected cells
was observed 36 h later, at 48 h following paclitaxel
treatment, suggesting that autophagic flux precedes cas-
pase activity following paclitaxel exposure of CERT-
depleted cells.
CERT depletion induces localization of LAMP2/LC3
and the accumulation of lysosomal structures in the
presence of paclitaxel
The localization of endogenous LAMP2 expression
was addressed following CERT depletion in GFP–
LC3–HEK293 cells, which stably express GFP–LC3,
by fixed cell immunofluorescence in the presence of
the lysosomal acidification inhibitor Bafilomycin A1
to prevent GFP–LC3 degradation. We observed ele-
vated endogenous LAMP2 intensity, consistent with
an increase in LAMP2 expression, and co-localization
of GFP–LC3 with LAMP2 in siCERT/paclitaxel-
treated relative to siCON/paclitaxel HEK293 cells
(Figure 2D). Depletion of CERT resulted in a signifi-
cant increase in LAMP2 spot intensity (Mann–Whitney
U-test, p = 0.015), suggesting that lysosomal size
increases following CERT depletion and paclitaxel
treatment.
Electron microscopy (EM) analysis revealed an
increase in the number of cells with electron-dense
structures that may correspond to lysosomal or
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Figure 2. siCERT/paclitaxel initiates an autophagy-like response. (A) Heat map of autophagy gene set (as defined using Metacore from
GeneGo Inc.). Autophagy gene set was found to be differentially regulated in CERT-depleted cells treated with ceramide compared to
ceramide treatment of HCT116 cells with proficient CERT transport. (B) LC3I/II western blot analysis following CERT and LAMP2 silencing
and 24 h of paclitaxel exposure. (C) Graph showing corrected Caspase 3/7 activity of siCON/paclitaxel- and siCERT/paclitaxel-treated
HCT116 cells normalized to siCON/vehicle control over 72 h. Error bars represent SD over six replicates/condition. Below the graph is a
western blot analysis over the same time course, showing LC3 expression following siCON or siCERT transfection with vehicle control
or paclitaxel treatment. (D) Representative immunofluorescence microscopy images of siCON/paclitaxel and siCERT/paclitaxel cells in the
presence of Bafilomycin A1. Blue corresponds to DAPI staining, green to GFP–LC3 and red to LAMP2. (E) Scatter plot of LAMP2 intensity
per spot following siCON, siCERT, siLAMP2 or siCERT and siLAMP2 silencing and treatment with 25 nM paclitaxel. Each dot represents a
replicate well. Horizontal lines signify mean and SD. (F) Graph of relative cell numbers following transfection of siCON or siRNAs targeting
regulators of autophagy. Data were normalized to cell number in siCON/vehicle control and siCON/paclitaxel for paclitaxel-treated
experiments. Error bars represent SDs across six replicates/condition. (G) Graph of relative cell number in paclitaxel-treated compared to
vehicle control following transfection of siCON, siCERT, siATG7 or siCERT and siATG7. Treated/control ratio for siCON was set to 1. Error
bars represent SDs across six replicates/condition.
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autophagosomal structures in siCERT/paclitaxel-
treated cells in contrast to siCON/paclitaxel-treated
cells (see Supporting information, Figures S2A, B.
Percentage of cells with electron-dense structures
with siCERT/paclitaxel: 75%, n = 24 versus siCON/
paclitaxel: 44%, n = 27, p = 0.045, Fisher’s exact
test). In contrast, co-depletion of CERT and LAMP2
in the presence of paclitaxel significantly reduced the
number of cells with these electron-dense structures
compared to siCERT/paclitaxel-treated cells (siCERT/
siLAMP2/paclitaxel: 32% versus siCERT/Paclitaxel
75%, n = 25 and n = 24 respectively; p = 0.004,
Fisher’s exact test), suggesting that specific changes to
the cellular ultrastructure occur in siCERT/paclitaxel-
treated cells (see Supporting information, Figure S2A).
Relationship of paclitaxel response with autophagy
gene expression
To explore the relationship of autophagy with pacli-
taxel response, we addressed whether silencing other
components of the autophagy pathway might influence
paclitaxel sensitivity. Silencing ATG7 induced pacli-
taxel resistance, indicating that a proximal member
of the autophagy pathway may influence paclitaxel
response (Figure 2F). Phenocopying LAMP2 silenc-
ing, co-depletion of both ATG7 and CERT significantly
attenuated CERT-mediated cell death (Mann–Whitney
U-test, p = 0.002) (Figure 2G).
CERT depletion promotes mitotic catastrophe that
is LAMP2-dependent
We sought to establish the cell-cycle fate of indi-
vidual cells following paclitaxel treatment and CERT
silencing, through live cell microscopy imaging of
H2B–GFP-labelled HCT116 cells during 48 h of
paclitaxel exposure. Paclitaxel stabilizes microtubules,
resulting in mitotic arrest [16] leading to death in mito-
sis or death following mitotic slippage into interphase
[17]. Paclitaxel treatment of siCON-transfected cells
promoted cell death following mitosis, or in interphase
cells following exposure to anti-mitotic agents as previ-
ously reported [18]. CERT depletion induced two-fold
more death events over 48 h compared to control trans-
fected cells following paclitaxel treatment (Figure 3A,
B) that mostly occurred during a multinucleated inter-
phase resulting from an aberrant mitosis. Co-depletion
of LAMP2 with CERT reversed paclitaxel sensitiza-
tion during 48 h of paclitaxel exposure (Figure 1C).
Paclitaxel-induced cell death was still observed in
interphase cells but LAMP2 depletion abrogated the
majority of mitotic and post-mitotic cell death events,
with the majority of multinucleated cells surviving
to the end of the observation period. Taken together,
these data suggest that CERT depletion promotes the
elimination of multinucleated polyploid cells following
paclitaxel exposure and this is LAMP2-dependent.
CERT is over-expressed in HER2+ primary breast
cancer
Next, we determined the expression of CERT in a panel
of cancer cell lines by qPCR to attempt to identify
cancer subtypes in which CERT expression may play
a role (Figure 4A). Breast cancer cell lines displayed
the broadest distribution of CERT expression. Analy-
sis of four HER2+ and eight HER2− breast cancer cell
lines revealed higher relative CERT expression in the
HER2+ cell lines compared to HER2− cancer cell lines
(p = 0.006, t-test; Figure 4A). We identified 12 breast
cancer datasets for which CERT expression was mea-
sured by microarray analysis. CERT mRNA expres-
sion was significantly repressed in basal breast cancers
(p = 1.41e-51) relative to other intrinsic subtypes of
breast cancer (see Supporting information, Figure S3A,
B). Next we assessed CERT protein expression in a
tissue microarray (TMA) panel of 356 primary breast
cancers of mixed ER/HER2 receptor subtype, tumour
grade and nodal status (Table 1). CERT protein expres-
sion, determined by the quickscore (CERT expression
intensity × percentage of cells positive) [7], was signif-
icantly elevated in HER2+ relative to HER2− primary
breast cancers (Wilcoxon test, p = 0.0009; Figure 4B;
for representative images; see Supporting information,
Figure S4A) with no significant difference between
ER+ and ER− subtypes (p = 0.0889).
CERT depletion sensitizes HER2+ breast cancer cell
lines to cytotoxics and induces autophagic flux
Next we assessed drug sensitivity in three HER2+
breast cancer cell lines, BT474, HCC1954 and SKBR3,
following CERT silencing. CERT depletion resulted in
multidrug sensitization to clinically relevant cytotox-
ics, paclitaxel, doxorubicin and cisplatin (Figure 4C).
CERT depletion in the HCC1954 cell line resulted in
decreased levels of LC3-I and LC3-II following treat-
ment with paclitaxel, cisplatin or doxorubicin when
compared to siCON-transfected cells (Figure 4D), sug-
gesting that, concordant with the HCT116 analy-
ses, increased autophagic flux occurs following CERT
depletion and cytotoxic drug treatment in HER2+
breast cancer cells.
Next, the HCC1954 cell line was transfected with
siCON, siCERT, siLAMP2 or siCERT and siLAMP2
and treated with either paclitaxel or doxorubicin,
used in the management of high-risk breast can-
cer in the adjuvant setting (Figure 4E). In all con-
ditions, LAMP2 co-silencing resulted in a signifi-
cant attenuation of CERT depletion-induced drug sen-
sitization (Mann–Whitney U-test: paclitaxel 50 nM,
p = 0.0087; paclitaxel 500 nM, p = 0.0043; doxoru-
bicin 250 nM, p = 0.0087; doxorubicin 1000 nM, p =
0.015). CERT depletion also resulted in trastuzumab
sensitization (see Supporting information, Figure S4B;
Mann–Whitney U-test, p = 0.0087).
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Figure 3. Live cell imaging and single cell fate analysis following CERT silencing and paclitaxel treatment. (A) Graph of single cell fate
analysis during paclitaxel exposure following transfection with siCON, siCERT, or siCERT and siLAMP2. Cells were individually tracked
for 48 h following paclitaxel treatment. Timing of entry into mitosis was scored from the time of nuclear envelope breakdown (NEB)
to reformation of nuclei. (B) Example of a time-lapse sequence (t , time in min) of a CERT-depleted cell treated with paclitaxel over
1200 min following mitotic entry. The cell undergoes nuclear envelope breakdown (NEB), followed by an aberrant mitosis resulting in a
multinucleated interphase and subsequently cell death.
CERT expression is associated with breast cancer
adjuvant chemotherapy survival outcome
Next, we attempted to address whether low CERT
expression might be associated with improved breast
cancer-specific survival (BCSS), particularly in primary
breast cancers treated with adjuvant chemotherapy in
the 356 primary breast cancer TMA cohort. We used
maximally selected rank statistics [8] to derive a thresh-
old for separating tumours into cohorts of low and
high CERT expression based on survival outcome. This
method selects an optimal threshold for prediction,
avoiding the erroneous reporting of over-optimistic low
p values by adjusting for multiple testing inherent in
the selection of the threshold. We obtained a CERT
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Figure 4. CERT is over-expressed in HER2+ primary breast cancer and is associated with poor prognosis. (A) Graph of relative CERT cDNA
expression in cell lines of various tissue origins. Horizontal lines signify median and interquartile range. (B) Graph demonstrates CERT
protein intensity in a breast cancer TMA cohort of 356 primary breast cancers divided into various subtypes, based on ER and HER2 receptor
status. The length of the whiskers was limited by maximal = 1.5 times the interquartile range. (C) Graph showing relative cell number
compared to vehicle control of HER2+ breast cancer cell lines, BT474, HCC1954 and SKBR3, following either siCON or siCERT transfection
and treatment with paclitaxel, cisplatin or doxorubicin. (D) Western blot demonstrating LC3-I and LC3-II expression in HCC1954 cells
following 48 h of CERT depletion, followed by 24 h of treatment with paclitaxel, cisplatin or doxorubicin. (E) Scatter plot of cell number
(as measured by fluorescence activity) in paclitaxel-treated (50 and 500 nM)(left) and doxorubicin-treated (250 and 1000 nM)(right)
HCC1954 cells following transfection with siCON, siCERT, siLAMP2 or siCERT and siLAMP2. Each dot represents a replicate well. Horizontal
lines signify mean and SD.
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Table 1. Demographic data of patients in breast cancer TMA cohort
All patients (n = 426) CERT low (n = 271) CERT high (n = 102)
Median age, years (range) 58 (27–92) 58 (30–90) 59 (27–92)
Unknown 2 2 0
Median size, mm (range) 20 (1–130) 19 (1–100) 20 (6–130)
Unknown 13 11 1
Grade, n (%)
1 98 (23) 67 (25) 11 (11)
2 184 (43) 127 (47) 43 (42)
3 143 (34) 76 (28) 48 (47)
Unknown 1 1 0
Lymph node status, n (%)
Positive 215 (53) 125 (48) 63 (65)
Negative 192 (47) 134 (52) 34 (35)
Unknown 19 12 5
Stage, n (%)
T1, 0–2 cm 246 (60) 163 (62) 54 (53)
T2, 2–5 cm 149 (36) 90 (35) 39 (39)
T3 >5 cm 18 (4) 7 (3) 8 (8)
Unknown 13 11 1
ER status, n (%)
Positive 326 (78) 216 (80) 75 (74)
Negative 92 (22) 54 (20) 27 (26)
Unknown 8 1 0
HER2 status, n (%)
Positive 31 (7) 11 (4) 18 (18)
Negative 393 (93) 258 (96) 84 (82)
Unknown 2 2 0
PR status, n (%)
Positive 300 (79) 198 (78) 79 (79)
Negative 80 (21) 57 (22) 21 (21)
Unknown 46 16 2
Chemotherapy, n (%)
Yes 149 (49) 100 (48) 41(49)
No 157 (51) 107 (52) 43 (51)
Unknown 120 64 18
quickscore of <175 and >175 for separating tumours
into low and high CERT expression, respectively. Sig-
nificantly poorer breast cancer outcome was observed
across all patients with primary breast cancers, with a
CERT quickscore >175 compared to patients with a
CERT quickscore <175 (HR 2.2 95% CI 1.3–3.6, p =
0.003; Figure 5A). A similar relationship was observed
when the analysis was restricted to HER2+ breast can-
cer patients only (Figure 5B; p = 0.035 HR 6.81). In
a multivariate Cox regression model, the association
of CERT expression with survival acts as a signif-
icant independent prognostic variable (Table 2). The
relationship between CERT expression and relapse-free
survival was further supported in a meta-analysis of
1861 patients with primary breast cancer, using the
publicly available Kaplan–Meier meta-analysis tool
[19] (see Supporting information, Figure S4C), HR 1.2
(1.1–1.4), p = 0.027).
We asked whether the relationship of low CERT
expression with significantly improved outcome was
observed when patients were stratified by use of adju-
vant chemotherapy. Low CERT expression in the 356
patient TMA cohort was associated with significantly
improved outcome in patients treated with adjuvant
chemotherapy [Figure 5C, n = 134, HR 2.2 (1.2–5.5),
p = 0.014]. In a similarly powered analysis of 150
patients who did not receive adjuvant chemotherapy
from within this cohort, there was no such significant
association of low CERT expression with improved
outcome (Figure 5D), suggesting that CERT expres-
sion may predict outcome, specifically in patients with
primary breast cancer receiving chemotherapy.
Discussion
Through transcriptomic and functional genomics-based
approaches, we have identified that CERT depletion
and paclitaxel exposure accelerate autophagic flux
in both colon and breast cancer models and results
in LAMP2-dependent death of multinucleated cells.
Accumulating evidence supports the importance of
autophagy in the response to cytotoxic drug or radiation
therapy that may enhance death or augment cancer cell
viability [20–24]. We previously identified the lysoso-
mal enzymes GBA1 and GBA3 as regulators of pacli-
taxel sensitivity [2], and microtubule stabilizing drugs
initiate lysosomal cathepsin B activation and release,
inhibition of which promotes resistance to this class of
drug [14].
Expression of an autophagy gene module is sig-
nificantly enriched following CERT silencing and
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Figure 5. CERT expression is associated with survival outcome
[breast cancer-specific survival (BCSS)] in patients with primary
breast cancer treated with adjuvant chemotherapy. (A) CERT
immunohistochemistry in 356 primary breast cancers and
Kaplan–Meier analysis of high CERT expression compared to
tumours with low CERT expression (quickscore >175 versus <175).
(B) Kaplan–Meier analysis of high CERT expression compared to
tumours with low CERT expression (quickscore >175 versus <175),
restricted to HER2+ breast cancer patients (n = 29) within the
same cohort of 356 patients. (C) Kaplan–Meier analysis of high
CERT expression compared to tumours with low CERT expression
(quickscore >175 versus <175), restricted to patients treated with
adjuvant chemotheraphy (n = 134) within the same cohort of
356 patients. (D) Kaplan–Meier analysis of high CERT expression
compared to tumours with low CERT expression (quickscore >175
versus <175), restricted to patients treated without adjuvant
chemotheraphy (n = 150) within the same cohort of 356 patients.
ceramide treatment. We suggest that the autophagy
transcriptional response may reflect accumulation of
ceramide within the ER, consistent with previous
reports of autophagy initiation by ceramide [25,26]
and the transcriptional regulation of autophagy [27].
Through this analysis, we suggest an explanation for
the synergistic activities of CERT depletion and pacli-
taxel exposure that may provide a molecular basis for
the elimination of multinucleated polyploid cells fol-
lowing an aberrant mitosis. We speculate that expres-
sion of LAMP2 primes the cell for completion of the
autophagic process, but alone is insufficient to drive
cell death. Cell death following CERT depletion and
drug exposure may result from the combination of the
synergistic rise in ER-restricted cellular ceramide and
autophagy gene expression coordinated with LAMP2
expression. Consistent with this model, we observed
co-localization of LAMP2 and LC3 in the presence
of lysosomal inhibitors in HEK293 cells, as well as
a reduction of LC3-I and LC3-II in CERT-depleted
cells treated with paclitaxel. Furthermore, abrogation
of the siCERT multidrug sensitizing phenotype and the
death of multinucleated cells was observed following
LAMP2 silencing.
Multinucleation may be a precursor of mononucle-
ate aneuploidy/polyploidy and CIN [28–30]. We have
shown that autophagic flux and the consequent death
of multinucleated cells following paclitaxel exposure
is dependent upon LAMP2 induction following CERT
depletion. Aneuploid cells display an increased sus-
ceptibility to compounds that interfere with protein
folding, and trisomic MEFs display increased LC3 lipi-
dation relative to wild-type MEFs [31]. These data sup-
port our observations that CERT depletion and pacli-
taxel treatment induces the unfolded protein response
[2], autophagic flux and the specific death of multinu-
cleated cells.
CERT is relatively over-expressed in HER2+ breast
cancer and CERT silencing sensitizes HER2+ breast
cancer cell lines to paclitaxel, doxorubicin, cisplatin
and trastuzumab. Cytotoxic multidrug sensitization is
associated with accelerated autophagic flux, which
appears to be LAMP2-dependent. Consistent with the
drug-sensitizing phenotype following CERT silencing,
low expression of CERT predicts improved breast
cancer outcome following adjuvant chemotherapy.
Prospective validation of the potential role for CERT in
predicting outcome following adjuvant chemotherapy
in breast cancer is in progress.
In summary, CERT expression may confer prognos-
tic utility in breast cancer and there may be thera-
peutic potential in the targeting of CERT to augment
autophagy and the death of multinucleated cells to limit
the initiation of chromosomal instability, intra-tumour
heterogeneity and chemotherapy resistance.
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